WO2002069232A3 - Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity - Google Patents

Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity Download PDF

Info

Publication number
WO2002069232A3
WO2002069232A3 PCT/EP2002/001688 EP0201688W WO02069232A3 WO 2002069232 A3 WO2002069232 A3 WO 2002069232A3 EP 0201688 W EP0201688 W EP 0201688W WO 02069232 A3 WO02069232 A3 WO 02069232A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
cell epitopes
immunogenicity
reeduced
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/001688
Other languages
French (fr)
Other versions
WO2002069232A2 (en
Inventor
Francis J Carr
Graham Carter
Tim Jones
Stephen Williams
Anita Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0207281-5A priority Critical patent/BR0207281A/en
Priority to EP02726112A priority patent/EP1366455B1/en
Priority to HU0303199A priority patent/HUP0303199A2/en
Priority to US10/468,496 priority patent/US7430476B2/en
Priority to ES02726112T priority patent/ES2309167T3/en
Priority to AU2002256624A priority patent/AU2002256624B2/en
Priority to DE60227344T priority patent/DE60227344D1/en
Priority to CA002438652A priority patent/CA2438652A1/en
Priority to MXPA03007316A priority patent/MXPA03007316A/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to PL02362414A priority patent/PL362414A1/en
Priority to JP2002568279A priority patent/JP4279554B2/en
Priority to KR1020037010860A priority patent/KR100899970B1/en
Publication of WO2002069232A2 publication Critical patent/WO2002069232A2/en
Publication of WO2002069232A3 publication Critical patent/WO2002069232A3/en
Anticipated expiration legal-status Critical
Priority to ZA2003/07324A priority patent/ZA200307324B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.
PCT/EP2002/001688 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity Ceased WO2002069232A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MXPA03007316A MXPA03007316A (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity.
HU0303199A HUP0303199A2 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US10/468,496 US7430476B2 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
ES02726112T ES2309167T3 (en) 2001-02-19 2002-02-18 METHOD FOR IDENTIFYING T-CELL EPITOTS AND METHOD FOR PREPARING MOLECULES WITH REDUCED IMMUNOGENICITY.
AU2002256624A AU2002256624B2 (en) 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
DE60227344T DE60227344D1 (en) 2001-02-19 2002-02-18 METHOD FOR THE IDENTIFICATION OF T-CELL PITOPES AND THEIR APPLICATION FOR THE PREPARATION OF MOLECULES WITH REDUCED IMMUNOGENICITY
CA002438652A CA2438652A1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
BR0207281-5A BR0207281A (en) 2001-02-19 2002-02-18 Method for Identifying T-Cell Epitopes and Use for Preparing Reduced Immunogenicity Molecules
PL02362414A PL362414A1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP02726112A EP1366455B1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
JP2002568279A JP4279554B2 (en) 2001-02-19 2002-02-18 Method for identifying T cell epitopes and method for producing molecules having reduced immunogenicity
KR1020037010860A KR100899970B1 (en) 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for the preparation of molecules with reduced immunogenicity
ZA2003/07324A ZA200307324B (en) 2001-02-19 2003-09-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
EP01103954 2001-02-19
EP01103954.2 2001-02-19
EP01105777 2001-03-08
EP01105777.5 2001-03-08
EP01106538.0 2001-03-15
EP01106538 2001-03-15
EP01106536 2001-03-15
EP01106536.4 2001-03-15
EP01107012 2001-03-20
EP01107012.5 2001-03-20
EP01106899.6 2001-03-20
EP01106899 2001-03-20
EP01107568 2001-03-27
EP01107568.6 2001-03-27
EP01110220.9 2001-04-25
EP01110220 2001-04-25
EP01113228.9 2001-05-30
EP01113228 2001-05-30
EP01124965.3 2001-10-19
EP01124965 2001-10-19
EP01126859.6 2001-11-12
EP01126859 2001-11-12

Publications (2)

Publication Number Publication Date
WO2002069232A2 WO2002069232A2 (en) 2002-09-06
WO2002069232A3 true WO2002069232A3 (en) 2003-02-13

Family

ID=27581535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001688 Ceased WO2002069232A2 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Country Status (14)

Country Link
US (1) US7430476B2 (en)
EP (2) EP1998266A3 (en)
JP (1) JP4279554B2 (en)
KR (1) KR100899970B1 (en)
CN (1) CN100404673C (en)
AT (1) ATE400030T1 (en)
AU (1) AU2002256624B2 (en)
CA (1) CA2438652A1 (en)
ES (1) ES2309167T3 (en)
HU (1) HUP0303199A2 (en)
MX (1) MXPA03007316A (en)
PL (1) PL362414A1 (en)
WO (1) WO2002069232A2 (en)
ZA (1) ZA200307324B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US7323549B2 (en) 2003-12-30 2008-01-29 Emd Lexigen Research Center Corp. IL-7 fusion proteins
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US8609094B2 (en) 2009-09-30 2013-12-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8691952B2 (en) 2005-12-30 2014-04-08 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9555110B2 (en) 2011-02-11 2017-01-31 Merck Patent Gmbh Anti-alpha-V integrin antibody for the treatment of prostate cancer
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10195281B2 (en) 2012-09-05 2019-02-05 Tracon Pharmaceuticals, Inc. Antibody formulations and uses thereof

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (en) * 1997-12-08 2016-11-24 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immunotherapy and general immune system stimulation
ES2267263T3 (en) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. COADMINISTRATION OF AN ANGIOGENESIS INHIBITOR TO REINFORCE THE IMMUNOLOGICAL RESPONSE THROUGH THE MEDIATION OF A FUSION PROTEIN OF A CYTOKIN WITH AN ANTIBODY.
DE60025480T2 (en) * 1999-05-14 2006-08-24 Mcgill University, Montreal METHODS OF IDENTIFYING MODULATORS OF INTERCHANGEABLE PROTEINS
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (en) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Multiple cytokine-antibody complexes.
KR20030064275A (en) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
RU2003129528A (en) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) METHOD FOR EXPRESSION OF PROTEINS CONTAINING AN ANTIBODY HYBRID ISOTYPE AS A COMPONENT
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
DK200101090A (en) 2001-07-12 2001-08-16 Novozymes As Subtilase variants
ATE469176T1 (en) * 2001-11-12 2010-06-15 Merck Patent Gmbh MODIFIED ANTI-TNF ANTIBODIES
KR20040068561A (en) * 2001-11-29 2004-07-31 메르크 파텐트 게엠베하 T-cell epitopes in carboxypeptidase g2
DK1454138T3 (en) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokines with modulated selectivity
AU2003213580A1 (en) * 2002-02-26 2003-09-09 Genencor International, Inc. Subtilisin carlsberg proteins with reduced immunogenicity
WO2003103715A1 (en) * 2002-06-11 2003-12-18 Merck Patent Gmbh Modified byrodin 1 with reduced immunogenicity
PL372862A1 (en) * 2002-08-09 2005-08-08 Merck Patent Gmbh T-cell epitopes in erythropoietin
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2006526414A (en) * 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド Deimmunized anti-CD3 antibody
WO2004113387A2 (en) * 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
MXPA06004035A (en) 2003-10-16 2006-08-31 Micromet Ag Multispecific deimmunized cd3-binders.
US7264806B2 (en) * 2003-11-01 2007-09-04 Biovation Ltd. Modified anti-CD52 antibody
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20050164308A1 (en) * 2003-12-18 2005-07-28 Fiona Harding Beta-lactamase CD4+ T-cell epitopes
RU2370276C2 (en) * 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ERYTHROPOIETIN FUSED PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
MXPA06010716A (en) * 2004-03-19 2007-02-21 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof.
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20060073563A1 (en) * 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
RU2437893C2 (en) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Il-7 versions with low immunising capacity
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
AU2012209017B2 (en) * 2005-02-03 2014-06-26 Antitope Limited Human antibodies and proteins
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
PL1966238T3 (en) 2005-12-30 2012-09-28 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US20080095756A1 (en) * 2006-09-05 2008-04-24 Biosynexus Incorporated Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
WO2009010290A2 (en) 2007-07-17 2009-01-22 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
CN101918532B (en) 2007-08-22 2016-03-30 普罗柏欧贞股份公司 Culture systems and methods for in vitro testing of immunogenicity and immune function
HRP20150279T1 (en) 2007-12-26 2015-05-08 Xencor, Inc. Fc variants with altered binding to fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2009110944A1 (en) 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
NO2700405T3 (en) 2008-05-29 2018-09-01
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SG175233A1 (en) * 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
WO2010124262A1 (en) * 2009-04-24 2010-10-28 Allostera Pharma Inc. Methods of identification of allosteramers and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2778552A1 (en) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
TWI622402B (en) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 Folate receptor 1 antibodies and immunoconjugates and their use
EP2542574B1 (en) 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
JP2012041316A (en) * 2010-08-23 2012-03-01 Akita Univ New peptide and molecular chaperon-inducing agent and anticancer agent
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
ES2600616T3 (en) * 2011-03-14 2017-02-10 Phlogo Aps Interleukin-1 receptor antagonists
BR112013025415B1 (en) 2011-04-01 2021-03-16 Immunogen, Inc use of a folate antireceptor immunoconjugate 1 (folr1)
WO2012142142A2 (en) 2011-04-12 2012-10-18 Temple University - Of The Commonwealth System Higher Education Adiponectin receptor agonists and methods of use
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US20130216530A1 (en) * 2012-02-02 2013-08-22 Exagen Diagnostics, Inc. Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
TW202423993A (en) 2012-11-14 2024-06-16 美商再生元醫藥公司 Recombinant cell surface capture proteins
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modified toxins
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN113150145B (en) 2013-08-30 2025-02-14 伊缪诺金公司 Antibodies and assays for detecting folate receptor 1
WO2015074048A1 (en) * 2013-11-18 2015-05-21 Siscapa Assay Technologies, Inc. Measurement of gamma-carboxylation of proteins
WO2015143558A1 (en) 2014-03-27 2015-10-01 British Columbia Cancer Agency Branch T-cell epitope identification
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
AU2015343239B2 (en) 2014-11-05 2021-06-03 Memorial Sloan Kettering Cancer Center Methods of selecting T cell line and donor thereof for adoptive cellular therapy
KR101669140B1 (en) * 2015-04-28 2016-10-26 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
WO2017040832A1 (en) * 2015-09-01 2017-03-09 The Administrators Of The Tulane Educational Fund A method for cd4+ t-cell epitope prediction using antigen structure
CN116440279B (en) 2015-09-17 2026-02-24 伊缪诺金公司 Therapeutic combinations comprising anti-FOLR 1 immunoconjugates
US10913772B2 (en) * 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
KR101897122B1 (en) * 2016-03-09 2018-09-10 주식회사 바이오펩 Peptides for treating inflammatory diseases and use thereof
JP2019532103A (en) * 2016-10-04 2019-11-07 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ Peptide libraries and methods of use
KR101887577B1 (en) * 2016-10-19 2018-09-10 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN109206482B (en) * 2018-09-30 2021-12-10 福建蓝昊生物科技有限公司 Seaweed-derived short peptide for inhibiting digestive tract inflammation and application thereof
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
US20220144920A1 (en) * 2019-01-03 2022-05-12 Amgen Inc. Engineering monoclonal antibodies to improve stability and production titer
EP3757127A1 (en) * 2019-06-28 2020-12-30 Institute for Research in Biomedicine Deimmunized antibodies binding to alpha-4 integrin and uses thereof
CN110694056B (en) * 2019-10-25 2023-05-05 四川农业大学 A kind of FSH antigen and its preparation method and FSH vaccine containing the antigen
NZ793813A (en) * 2020-04-29 2025-12-19 Onegene Biotechnology Inc Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
CN112480245B (en) * 2020-12-19 2023-08-18 上海佰君生物科技有限公司 Application of a Hydrophobic Cyclic Peptide Ligand to Purify Human Immunoglobulin G
CN112457399B (en) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 A kind of purification method of human immunoglobulin G
CN116003573A (en) * 2022-05-30 2023-04-25 四川农业大学 A kind of follicle stimulating hormone beta subunit active peptide and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763257A (en) 1984-05-29 1998-06-09 Genencor International, Inc. Modified subtilisins having amino acid alterations
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK203187A (en) 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
NO176799C (en) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA encoding a polypeptide, recombinant plasmid that encodes and can express a polypeptide and method for producing this polypeptide
US4914031A (en) 1987-04-10 1990-04-03 Amgen, Inc. Subtilisin analogs
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2250213C2 (en) 1989-01-31 2005-04-20 Джеффри С. РУБИН Isolated keratinocyte growth factor (kgf) protein, recombinant dna molecule, vector, method for construction of host cell, method for protein production, and pharmaceutical composition
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
KR100188532B1 (en) 1989-05-17 1999-06-01 스티븐 엠. 오드리 Multiply mutated subtilisins
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (en) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF)
DE4105480A1 (en) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
DK0752248T3 (en) 1992-11-13 2000-11-13 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antibody
CA2166278A1 (en) 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5618714A (en) 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
DE69533921T2 (en) 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven METHOD FOR REDUCING MALFUNCTIONS OF IMMUNE SYSTEM AND HEMOSTASE DURING EXTRACORPOREAL CIRCULATION
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CU22615A1 (en) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6008328A (en) 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5869330A (en) 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
CA2275183A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
CZ298429B6 (en) 1997-04-28 2007-10-03 Eli Lilly And Company Stable lyophilized formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
EP1135493A2 (en) * 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietic compounds
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
HUP0105090A2 (en) 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Expression and export of anti-obesity proteins as fc fusion proteins
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ALTUVIA Y ET AL: "RANKING POTENTIAL BINDING PEPTIDES TO MHC MOLECULES BY A COMPUTATIONAL THREADING APPROACH", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 249, no. 1, 1995, pages 244 - 250, XP000925520, ISSN: 0022-2836 *
BOEHM H-J: "PREDICTION OF BINDING CONSTANTS OF PROTEIN LIGANDS: A FAST METHOD FOR THE PRIORITIZATION OF HITS OBTAINED FROM DE NOVO DESIGN OR 3D DATABASE SEARCH PROGRAMS", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, ESCOM SCIENCE PUBLISHERS BV, XX, vol. 4, no. 12, July 1998 (1998-07-01), pages 309 - 323, XP008004781, ISSN: 0920-654X *
BUUS S: "Description and prediction of peptide-MHC binding: the 'human MHC project'", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 2, April 1999 (1999-04-01), pages 209 - 213, XP004257525, ISSN: 0952-7915 *
CLEMENS ANDREAS ET AL: "The J558 VH CDR3 region contributes little to antibody avidity;however, it is the recognition element for cognate T cell control of the alpha(1fwdarw3) dextran-specific antibody response.", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 12, Q9QXE9, December 1998 (1998-12-01), pages 1931 - 1942, XP002217780, ISSN: 0953-8178, Retrieved from the Internet <URL:EBI> *
DATABASE EMBL [online] 1 May 2000 (2000-05-01), CLEMENS ET AL., XP002217781, retrieved from EBI Database accession no. Q9QXE9 *
FREMONT D H ET AL: "STRUCTURES OF AN MHC CLASS II MOLECULE WITH COVALENTLY BOUND SINGLEPEPTIDES", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 272, no. 5264, 17 May 1996 (1996-05-17), pages 1001 - 1004, XP000652224, ISSN: 0036-8075 *
GILLIES S D ET AL: "HIGH-LEVEL EXPRESSION OF CHIMERIC ANTIBODIES USING ADAPTED CDNA VARIABLE REGION CASSETTES", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 125, 1989, pages 191 - 202, XP002176400, ISSN: 0022-1759 *
GILLILAND L K ET AL: "Elimination of the Immunogenicity of Therapeutic Antibodies", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, 1999, pages 3663 - 3671, XP002212906, ISSN: 0022-1767 *
GRAY P W ET AL: "CLONING OF HUMAN TUMOR NECROSIS FACTOR (TNF) RECEPTOR CDNA AND EXPRESSION OF RECOMBINANT SOLUBLE TNF-BINDING PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 19, October 1990 (1990-10-01), pages 7380 - 7384, XP000160072, ISSN: 0027-8424 *
HIMMLER A ET AL: "MOLECULAR CLONING AND EXPRESSION OF HUMAN AND RAT TUMOR NECROSIS FACTOR RECEPTOR CHAIN P60 AND ITS SOLUBLE DERIVATIVE TUMOR NECROSIS FACTOR-BINDING PROTEIN", DNA AND CELL BIOLOGY, vol. 9, no. 10, 1990, pages 705 - 716, XP001118652, ISSN: 1044-5498 *
MARGALIT H ET AL: "PREDICTION OF IMMUNODOMINANT HELPER T CELL ANTIGENIC SITES FROM THE PRIMARY SEQUENCE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 138, no. 7, 1 April 1987 (1987-04-01), pages 2213 - 2229, XP002017181, ISSN: 0022-1767 *
MCCAFFERTY JOHN ET AL: "Engineering therapeutic proteins.", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 10, no. 4, August 2000 (2000-08-01), pages 417 - 420, XP002208679, ISSN: 0959-440X *
MEISTER G E ET AL: "Two novel T cell epitope prediction algorithms based on MHC-binding motifs;comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 6, 1 April 1995 (1995-04-01), pages 581 - 591, XP004057605, ISSN: 0264-410X *
NOPHAR Y ET AL: "SOLUBLE FORMS OF TUMOR NECROSIS FACTOR RECEPTORS (TNF-RS). THE CDNA FOR THE TYPE 1 TNF-R, CLONED USING AMINO ACID SEQUENCE DATA OF ITS SOLUBLE FORM, ENCODES BOTH THE CELL SURFACE AND A SOLUBLE FORM OF THE RECEPTOR", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 10, 1 October 1990 (1990-10-01), pages 3269 - 3278, XP002025930, ISSN: 0261-4189 *
REYES V E ET AL: "COMPARISON OF THREE RELATED METHODS TO SELECT T CELL-PRESENTED SEQUENCES OF PROTEIN ANTIGENS", MOLECULAR IMMUNOLOGY, vol. 27, no. 10, 1990, pages 1021 - 1028, XP001088988, ISSN: 0161-5890 *
ROGNAN DIDIER ET AL: "Predicting binding affinities of protein ligands from three-dimensional models: Application to peptide binding to class I major histocompatibility proteins.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 22, 4 November 1999 (1999-11-04), pages 4650 - 4658, XP002208678, ISSN: 0022-2623 *
ROTHBARD J B ET AL: "A SEQUENCE PATTERN COMMON TO T CELL EPITOPES", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 1, 1988, pages 93 - 100, XP000877127, ISSN: 0261-4189 *
SCHIRLE M ET AL: "Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 257, no. 1-2, 1 November 2001 (2001-11-01), pages 1 - 16, XP004311932, ISSN: 0022-1759 *
STERN L J ET AL: "CRYSTAL STRUCTURE OF THE HUMAN CLASS II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA VIRUS PEPTIDE", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 368, 17 March 1994 (1994-03-17), pages 215 - 221, XP002919456, ISSN: 0028-0836 *
STILLE C J ET AL: "HYDROPHOBIC STRIP-OF-HELIX ALGORITHM FOR SELECTION OF T CELL-PRESENTED PEPTIDES", MOLECULAR IMMUNOLOGY, vol. 24, no. 10, 1987, pages 1021 - 1028, XP001097883, ISSN: 0161-5890 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US7323549B2 (en) 2003-12-30 2008-01-29 Emd Lexigen Research Center Corp. IL-7 fusion proteins
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US8957195B2 (en) 2005-12-30 2015-02-17 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
US8691952B2 (en) 2005-12-30 2014-04-08 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
US9944714B2 (en) 2009-09-30 2018-04-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US9150652B2 (en) 2009-09-30 2015-10-06 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8609094B2 (en) 2009-09-30 2013-12-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US9518122B2 (en) 2009-09-30 2016-12-13 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9555110B2 (en) 2011-02-11 2017-01-31 Merck Patent Gmbh Anti-alpha-V integrin antibody for the treatment of prostate cancer
US10195281B2 (en) 2012-09-05 2019-02-05 Tracon Pharmaceuticals, Inc. Antibody formulations and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10336831B2 (en) 2014-11-12 2019-07-02 Tracon Pharmaceuticals, Inc. Use of anti-endoglin antibodies for treating ocular fibrosis

Also Published As

Publication number Publication date
KR20030075201A (en) 2003-09-22
CA2438652A1 (en) 2002-09-06
HUP0303199A2 (en) 2003-12-29
US20040180386A1 (en) 2004-09-16
EP1998266A2 (en) 2008-12-03
KR100899970B1 (en) 2009-05-28
JP4279554B2 (en) 2009-06-17
WO2002069232A2 (en) 2002-09-06
EP1366455A2 (en) 2003-12-03
ES2309167T3 (en) 2008-12-16
ATE400030T1 (en) 2008-07-15
PL362414A1 (en) 2004-11-02
EP1366455B1 (en) 2008-07-02
MXPA03007316A (en) 2003-12-04
AU2002256624B8 (en) 2002-09-12
EP1998266A3 (en) 2009-02-11
US7430476B2 (en) 2008-09-30
CN1493052A (en) 2004-04-28
CN100404673C (en) 2008-07-23
JP2004523754A (en) 2004-08-05
AU2002256624B2 (en) 2007-12-06
ZA200307324B (en) 2005-02-23

Similar Documents

Publication Publication Date Title
WO2002069232A3 (en) Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
DE60139542D1 (en) METHODS OF PREPARING HUMAN MONOCLONAL ANTIBODIES
WO2000056901A3 (en) Linear and circular expression elements
WO2002092836A3 (en) Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
WO2001047959A3 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP2287177A3 (en) Streptococcus agalactiae antigens I + II
WO1999057280A3 (en) Neisseria meningitidis antigens and compositions
WO2002062850A3 (en) Hybrid antibodies and uses thereof
WO2000044389A3 (en) Method for preparing membrane vesicles
BR9906927A (en) Neisseria meningitidis proteins
WO2005081911A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α
AU4120296A (en) Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines
WO2002012899A3 (en) Peptides presented by cells
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
WO2004106367A3 (en) Enterococcus antigens
EP2182065A3 (en) Staphylococcus epidermidis antigens
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
AU2001235530A1 (en) Method for synthesising and immobilising nucleic acids on a silanized solid support
WO2003048317A3 (en) Antibodies to magmas and uses thereof
MXPA03008587A (en) Method for producing a vaccine.
WO2005002512A3 (en) Immunotherapeutic vaccine strategy
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
WO2004003009A3 (en) Francisella tularensis immunogenic proteins and dna encoding these

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002726112

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007316

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002256624

Country of ref document: AU

Ref document number: 2438652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10468496

Country of ref document: US

Ref document number: 2002568279

Country of ref document: JP

Ref document number: 1020037010860

Country of ref document: KR

Ref document number: 028051572

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003/07324

Country of ref document: ZA

Ref document number: 200307324

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020037010860

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002726112

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002726112

Country of ref document: EP